-
-
This randomized, controlled, open-label, multicenter Phase 3 trial compared axitinib with sorafenib as second-line therapy for metastatic renal clear-cell cancer. The results showed that axitinib extended progression-free survival by 2 months more than sorafenib (6.7 months vs 4.7 months), and had a superior objective response rate (19.4% vs 9.4%).
-
An asymptomatic 78-year-old retired accountant presented to his physician with intractable hiccups. Physical examination, complete blood count, and imaging studies did not reveal a cause of the hiccups, and after several days the symptom disappeared. However, upon review of the abdominal CT scan obtained in evaluation of the hiccups, a right renal mass was defined.
-
New treatment for prostate cancer; avastin and breast cancer; new CMS disclosure rule; and FDA actions.
-
New treatment for TB; safety of dabigatran; quality of antidepressants; systolic hypertension treatment; and FDA actions.
-
-
A 57-year-old postmenopausal librarian, who is 1-year post diagnosis of a stage II invasive cancer of the right breast, is found to be estrogen- and progesterone-receptor positive, and Her2neu negative with one positive axillary node.
-
A full panel of prognostic indicators was examined in 449 treatment-naïve CLL patients and it was found that serum light chain ratio was useful in confirming clonality. However, the sum of both k and l serum light chains proved of greater prognositc value in determining an early need to offer CLL treatment. A total (k + l) level of > 60.6 mg/mL was an independent predictor of limited treatment-free survival.
-
For patients who have synchronous bilateral breast cancer, overall survival has been shown to be less favorable than for patients presenting with unilateral disease. In the current matched case-control series, overall survival was comparable. Clinicians are advised to prescribe systemic therapy based upon the more aggressive of the two lesions.
-
The tyrosine kinase inhibitor dasatinib was added to docetaxel in the treatment of advanced castration-resistant prostate cancer in a Phase 1-2 trial. The combination was shown to be generally well-tolerated and to result in markers of reduced bone turnover in the great majority of patients and in durable PSA responses in approximately 50%. The findings justify proceeding to Phase 3 clinical trial.